References

References1. Sungkanuparph S, Sathapatayavongs B, Pracharktam R. Infections with rapidly growing mycobacteria: report of 20 cases. Int J Infect Dis 2003;7:198–205.SungkanuparphS]]SathapatayavongsB]]PracharktamRInfections with rapidly growing mycobacteria: report of 20 cases.Int J Infect Dis20037198-2052. Suttner NJ, Adhami Z, Aspoas AR. Mycobacterium chelonae lumbar spinal infection. Br J Neurosurg 2001;15:265–269.SuttnerNJ]]AdhamiZ]]AspoasARMycobacterium chelonae lumbar spinal infection.Br J Neurosurg200115265-2693. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chenonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992;166:405–412.WallaceRJJr]]BrownBA]]OnyiGOSkin, soft tissue, and bone infections due to Mycobacterium chelonae chenonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.J Infect Dis1992166405-4124. Miller AC, Commens CA, Jaroworski R, et al. The turtle’s revenge: a case of soft tissue Mycobacterium chelonae infection. Med J Aust 1990;153:493–495.MillerAC]]CommensCA]]JaroworskiR&etal;The turtle’s revenge: a case of soft tissue Mycobacterium chelonae infection.Med J Aust1990153493-4955. Centers for Disease Control and Prevention. Nontuberculous mycobacteria reported to the public health laboratory information system by state public health laboratories, 1993–1996. Atlanta, Georgia, US Department of Health and Human Services, 1999. Available at www.cdc.gov/tb/topic/laboratory/nontuberculosismycobacterium.pdf.6. Chapman JS. The ecology of the atypical mycobacteria. Arch Environ Health 1971;22:41–46.ChapmanJSThe ecology of the atypical mycobacteria.Arch Environ Health19712241-467. Gruft H, Falkinham JO III, Parker BC. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev Infect Dis 1981;3:990–996.GruftH]]FalkinhamJOIII]]ParkerBCRecent experience in the epidemiology of disease caused by atypical mycobacteria.Rev Infect Dis19813990-9968. Chang MA, Jain S, Azar DT. Infections following laser in situ keratomileusis: an integration of the published literature. Surv Ophthalmol 2004;49:269–280.ChangMA]]JainS]]AzarDTInfections following laser in situ keratomileusis: an integration of the published literature.Surv Ophthalmol200449269-2809. Jin D, Qu D, Chen J, et al. One-stage anterior interbody autografting and instrumentation in primary surgical management of thoracolumbar spinal tuberculosis. Eur Spine J 2004;13:114–121.JinD]]QuD]]ChenJ&etal;One-stage anterior interbody autografting and instrumentation in primary surgical management of thoracolumbar spinal tuberculosis.Eur Spine J200413114-12110. Wallace RJ Jr, Tanner D, Brennan PJ, et al. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993;119:482–486.WallaceRJJr]]TannerD]]BrennanPJ&etal;Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae.Ann Intern Med1993119482-48611. Brown-Elliott BA, Wallace RJ Jr, Blinkhorn R, et al. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001;33:1433–1434.Brown-ElliottBA]]WallaceRJJr]]BlinkhornR&etal;Successful treatment of disseminated Mycobacterium chelonae infection with linezolid.Clin Infect Dis2001331433-143412. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45:764–767.WallaceRJJr]]Brown-ElliottBA]]WardSC&etal;Activities of linezolid against rapidly growing mycobacteria.Antimicrob Agents Chemother200145764-76713. Wallace RJ, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46:3164–3167.WallaceRJ]]Brown-ElliottBA]]CristCJ&etal;Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.Antimicrob Agents Chemother2002463164-316714. Holland SM. Nontuberculous mycobacteria. Am J Med Sci 2001;321:49–55.HollandSMNontuberculous mycobacteria.Am J Med Sci200132149-5515. Pruit TC, Hughes LO, Blasier RD, et al. Atypical mycobacterial vertebral osteomyelitis in a steroid-dependent adolescent: a case report. Spine (Phila Pa 1976) 1993;18:2553–2555.PruitTC]]HughesLO]]BlasierRD&etal;Atypical mycobacterial vertebral osteomyelitis in a steroid-dependent adolescent: a case report.Spine (Phila Pa 1976)1993182553-255516. Oga M, Arizono T, Takasita M, et al. Evaluation of the risk of instrumentation as a foreign body in the spinal tuberculosis: clinical and biological study. Spine 1993;8:1890–1894.OgaM]]ArizonoT]]TakasitaM&etal;Evaluation of the risk of instrumentation as a foreign body in the spinal tuberculosis: clinical and biological study.Spine199381890-189417. Wallace RJ Jr, Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985;152:500–514.WallaceRJJr]]SwensonJM]]SilcoxVA&etal;Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.J Infect Dis1985152500-514